Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Lucid Diagnostics Inc. (LUCD:NASDAQ), powered by AI.
Lucid Diagnostics Inc. is currently trading at $1.02. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Lucid Diagnostics Inc. on Alpha Lenz.
Lucid Diagnostics Inc.'s P/E ratio is -2.9.
“Lucid Diagnostics Inc. trades at a P/E of -2.9 (undervalued) with modest ROE of -710.6%. 3Y revenue CAGR of 132.0% highlights clear growth momentum.”
Ask for details →Lucid Diagnostics Inc. is a medical technology company focusing on the early detection of esophageal precancer and cancer. Their key product line, EsoCheck, is an innovative diagnostic tool designed to aid in the identification of esophageal conditions such as Barrett's Esophagus. This offering is particularly significant as it provides a less invasive, more efficient alternative to traditional diagnostic methods like endoscopy. Operating primarily in the healthcare sector, Lucid Diagnostics aims to enhance early diagnosis rates, potentially improving patient outcomes by enabling earlier intervention. The company plays a crucial role in the early detection landscape, striving to increase awareness and availability of non-invasive diagnostic options. As a part of the broader MedTech industry, Lucid Diagnostics is aligned with the ongoing trend towards preventative healthcare solutions, positioning itself as a key player in improving patient care through technological innovation.
“Lucid Diagnostics Inc. trades at a P/E of -2.9 (undervalued) with modest ROE of -710.6%. 3Y revenue CAGR of 132.0% highlights clear growth momentum.”
Ask for details →Lucid Diagnostics Inc. (ticker: LUCD) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 72 employees. Market cap is $167M.
The current price is $1.02 with a P/E ratio of -2.89x and P/B of 15.31x.
ROE is -710.60% and operating margin is -1054.82%. Annual revenue is $5M.